经皮左心耳封堵术临床应用及研究进展

doi:10.3877/cma.j.issn.2095-8757.2017.03.006

心房颤动（简称房颤）是在老年人中十分常见的一种心律失常，非瓣膜病房颤患者左心房血栓90%以上存在于左心耳，风湿性瓣膜病患者60%脑卒中栓子来源于左心耳。华法林是预防房颤血栓栓塞最主要的治疗方法，但华法林可导致出血风险增加、需定期监测凝血酶原国际标准化比值、治疗窗狭窄、与其他药物及食物会出现相互反应等不良事件。而新型口服抗凝药价格昂贵，依从性不确定、漏服风险增加、缺乏拮抗剂，且部分患者对抗凝药反应较差或存在抗凝禁忌证，导致其临床应用相对不足。近年来，多项大型临床研究证实经皮左心耳封堵（percutaneous left atrial appendage occlusion, PLAAO）可以有效降低房颤患者脑卒中的发生率。本文旨在对PLAAO术的相关研究及最新进展作一综述，以期为临床提供参考。

关键词: 心房颤动, 经皮左心耳封堵术, 脑卒中, 研究进展

Atrial fibrillation (Af) is a common type of arrhythmia in the elderly. More than 90% of left atrial thrombosis in non-valvular disease Af and over 60% of stoke embolus in rheumatic valvular disease occur in left atrial appendage. Warfarin is the main treatment method for preventing atrial thromboembolism. However, it may lead to increased risk of bleeding. Prothrombin international standardization ratio needs to be regularly monitored. Warfarin has narrow therapeutic window, and has interaction and adverse effects with other drugs and food. Novel oral anticoagulants are expensive, has compliance uncertainty and increased risk of leakage suit. They also lack antagonists, and some patients exist poor response to anticoagulants or anticoagulant contraindicated, lead to the relatively insufficient clinical application. In recent years, several large clinical studies confirm that percutaneous left atrial appendage occlusion (PLAAO) can effectively reduce the incidence of stroke in Af patients. This paper aims to provide a review of the research and latest development of the PLAAO.

Key words: Atrial fibrillation, Percutaneous left atrial appendage occlusion, Stroke, Research progress

[1]	Sick PB, Schuler G, Hauptmann KE, et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation[J].J Am Coll Cardiol, 2007, 49(13): 1490-1495.
[2]	Pheerawong P, Songmuang SB, Lertsuwunseri V, et al. Clinical results of left atrial appendage closure with watchman device in patients with atrial fibrillation[J]. J Med Assoc Thai, 2015, 98(10): 942-949.
[3]	Wiebe J, Franke J, Lehn K, et al. Percutaneous left atrial appendage closure with the watchman device long-term results up to 5 years[J]. JACC Cardiovasc Interv, 2015, 8(15): 1915-1921.
[4]	Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation:a randomised non-inferiority trial[J].Lancet, 2009, 374(9689): 534-542.
[5]	姬国华，杨栋，张邢炜，等.16例房颤患者左心耳封堵术的围手术期护理及随访[J].中华全科医学, 2015, 13(11): 1861-1863.
[6]	吴小三，方传勤.CHADS2评分在非瓣膜病心房颤动患者发生缺血性脑卒中短期预后的预测价值[J].中华老年心脑血管病杂志, 2015, 17(10): 1055-1057.
[7]	Giralt-Steinhauer E, Cuadrado-Godia E, Ois A, et al. Comparison between CHADS2 and CHA2 DS2-VASc score in a stroke cohort with atrial fibrillation[J]. Eur J Neurol, 2013, 20(4): 623-628.
[8]	Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation[J]. Ann Intern Med, 2007, 146(12): 857-867.
[9]	Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience[J]. Circulation, 2002, 105(16): 1887-1889.
[10]	Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for embolic protection in patients with AF (PROTECT AF) clinical trial and the Continued Access Registry[J]. Circulation, 2011, 123(4): 417-424.
[11]	Reddy VY, Doshi SK, Sievert H, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) trial[J]. Circulation, 2013, 127(6): 720-729.
[12]	Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial[J]. J Am Coll Cardiol, 2014, 64(1): 1-12.
[13]	肖云云，徐伟，徐标.经皮左心耳封堵术的有效性与安全性[J].医学研究生学报, 2015, 28(5): 553-556.
[14]	Park JW, Bethencourt A, Sievert H, et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience[J]. Catheter Cardiovasc Interv, 2011, 77(5): 700-706.
[15]	何璐，张玉顺.经皮左心耳封堵术预防心房颤动血栓栓塞的应用前景[J].心血管病学进展, 2013, 34(5): 604-607.
[16]	Park J, Sievert H, Omran H, et al. Tct-112 interim data from amplatzer cardiac plug registry[J]. J Am Coll Cardiol, 2011, 58(20): 33-36.
[17]	姚青，宋治远，舒茂琴，等.Watchman左心耳封堵器的临床应用[J].第三军医大学学报, 2014, 36(20): 2129-2132.
[18]	杨思共，张恒.经皮左心耳封堵装置预防心房颤动血栓新进展[J].安徽医药, 2017, 21(3): 430-434.
[19]	Bartus K, Han FT, Bednarek J, et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience[J]. J Am Coll Cardiol, 2013, 62(2): 108-118.
[20]	Price MJ, Gibson DN, Yakubov SJ, et al. Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation consortium[J]. J Am Coll Cardiol, 2014, 64(6): 565-572.
[21]	Afzal MR, Kanmanthareddy A, Earnest M, et al. Impact of left atrial appendage exclusion using an epicardial ligation system (LARIAT) on atrial fibrillation burden in patients with cardiac implantable electronic devices[J]. Heart Rhythm, 2015, 12(1): 52-59.
[22]	Starck CT, Steffel J, Emmert MY, et al. Epicardial left atrial appendage clip occlusion also provides the electrical isolation of the left atrial appendage[J]. Interact Cardiovasc Thorac Surg, 2012, 15(3): 416-418.
[23]	Di Biase L, Burkhardt JD, Mohanty P, et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio[J]. Circulation, 2010, 121(23): 2550-2556.
[24]	Kawamura M, Scheinman MM, Lee RJ, et al. Left atrial appendage ligation in patients with atrial fibrillation leads to a decrease in atrial dispersion[J]. J Am Heart Assoc, 2015, 4(5).pii: e001581.
[25]	Majunke N, Sandri M, Adams V, et al. Atrial and brain natriuretic peptide secretion after percutaneous closure of the left atrial appendage with the Watchman device[J]. J Invasive Cardiol, 2015, 27(10): 448-452.
[26]	Cruz-Gonzalez I, Palazuelos Molinero J, Valenzuela M, et al. Brain natriuretic peptide levels variation after left atrial appendage occlusion[J]. Catheter Cardiovasc Interv, 2016, 87(1): E39-43.
[27]	Behnes M, Sartorius B, Wenke A, et al. Percutaneous closure of left atrial appendage affects Mid-Term release of MR-pro ANP[J]. Sci Rep, 2017, 7(1): 9028.
[28]	Bösche LI, Afshari F, Schöne D, et al. Initial experience with novel oral anticoagulants during the first 45 days after left atrial appendage closure with the Watchman device[J].Clin Crdiola, 2015, 38(12): 720-724.
[29]	Seeger J, Bothner C, Dahme T, et al. Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk[J]. Clin Res Cardiol, 2016, 105(3): 225-229.
[30]	Bonnet G, Salaun E, Pankert M, et al. Initial experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation: A single-centre registry[J]. Arch Crdiovasc Dis, 2016, 109(12): 689-695.
[31]	Wiebe J, Bertog S, Franke J, et al. Safety of percutaneous left atrial appendage closure with the Amplatzer cardiac plug in patients with atrial fibrillation and contraindications to anticoagulation[J]. Catheter Cardiovasc Interv, 2014, 83(5): 796-802.
[32]	Barakat AF, Hussein AA, Saliba WI, et al. Initial experience with high-risk patients excluded from clinical trials: safety of short-term anticoagulation after left atrial appendage closure device[J]. Circ Arhrythm Electrophysiol, 2016, 9(6).pii: e004004.
[33]	Fahmy P, Spencer R, Tsang M, et al. Left atrial appendage closure for atrial fibrillation is safe and effective after intracranial or intraocular hemorrhage[J].Can J Cardiol, 2016, 32(3): 349-354.
[34]	陈涵.左心耳封堵术后用药再起波澜[J].心电与循环, 2017, 36(4): 281.

[1]	刘丹妮, 敖梦, 冉海涛, 李世玉, 秦芳. 三维超声心动图及二维斑点追踪成像对持续性心房颤动复律后双心房逆向重构的评估[J]. 中华医学超声杂志（电子版）, 2023, 20(08): 827-835.
[2]	樊逸隽, 杨枫, 王玮, 殷鹤英, 刘俊. 喉前淋巴结转移对甲状腺乳头状癌诊疗价值的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(04): 306-310.
[3]	张林, 刘芳, 赵静, 刘勇, 周青. 远程康复在慢性阻塞性肺疾病患者肺康复中的研究进展[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 601-604.
[4]	蓝冰, 王怀明, 王辉, 马波. 局部晚期结肠癌膀胱浸润的研究进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 505-511.
[5]	尚慧娟, 袁晓冬. 机械取栓术后应用依达拉奉右崁醇对急性缺血性脑卒中预后的改善[J]. 中华神经创伤外科电子杂志, 2023, 09(05): 295-301.
[6]	廖家权, 吴波, 唐昌敏. 体外冲击波联合肌电生物反馈对脑卒中后足下垂的影响[J]. 中华脑科疾病与康复杂志(电子版), 2023, 13(05): 286-292.
[7]	许方军, 曹晓光, 王修敏, 董学超, 刘云卫, 彭云飞, 周康. 虚拟情景互动技术联合肩胛骨运动控制强化训练对偏瘫患者上肢功能及日常生活活动能力的影响[J]. 中华脑科疾病与康复杂志(电子版), 2023, 13(04): 222-228.
[8]	吴一菡, 雷章, 卢宏达. MUC16/CA125在良恶性肿瘤诊治中的作用及其研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(05): 591-595.
[9]	王震, 杨晓月, 苏康康, 王朝阳, 李少杰, 陈淑霞, 谷剑. β受体阻滞剂对心力衰竭合并房颤患者预后影响的研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(04): 479-482.
[10]	孙畅, 赵世刚, 白文婷. 脑卒中后认知障碍与内分泌激素变化的关系[J]. 中华脑血管病杂志(电子版), 2023, 17(05): 471-476.
[11]	张许平, 刘佳成, 张舸, 杜艳姣, 李韶, 商丹丹, 王浩, 李艳, 段智慧. CYP2C19基因多态性联合血栓弹力图指导大动脉粥样硬化型非致残性缺血性脑血管事件患者抗血小板治疗的效果[J]. 中华脑血管病杂志(电子版), 2023, 17(05): 477-481.
[12]	杨海华, 袁景林, 周晓梅, 牛军伟. RNF213基因突变所致烟雾病一家系病例临床分析并文献复习[J]. 中华脑血管病杂志(电子版), 2023, 17(05): 495-498.
[13]	李昕, 李永凯, 江树青, 夏来百提姑·赛买提, 杨建中. 急性缺血性脑卒中静脉溶栓后出血转化相关危险因素分析[J]. 中华脑血管病杂志(电子版), 2023, 17(04): 331-336.
[14]	邓颖, 黄山, 胡慧秀, 孙超. 老年缺血性脑卒中患者危险因素聚集情况分析[J]. 中华脑血管病杂志(电子版), 2023, 17(04): 344-349.
[15]	祁研, 张岩, 陈雪, 刘颖, 史楠. 探讨高低频交互rTMS对老年脑卒中偏瘫患者肢体功能、吞咽功能及日常生活活动能力的影响[J]. 中华脑血管病杂志(电子版), 2023, 17(04): 359-363.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Clinical application and advances of percutaneous left atrial appendage occlusion

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Clinical application and advances of percutaneous left atrial appendage occlusion